ArticleFrontiers in microbiology2026
Spatiotemporal dynamics and genotypic shift of Coxsackievirus A16 in Fujian, China, from 2010 to 2025.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite the diverse etiology of hand, foot, and mouth disease (HFMD), Coxsackievirus A16 (CVA16) persists as a dominant pathogen in the Asia-Pacific region. This study characterizes the molecular epidemiological evolution of CVA16 in Fujian Province from 2010 to 2025 to understand its changing prevalence and genetic evolution. Methods: We analyzed the temporal, spatial, and demographic distributions of CVA16-HFMD in Fujian Province from 2010 to 2025, and further investigated the phylogenetic characteristics via MEGA and BEAST software. Results: From 2010 to 2025, laboratory-confirmed CVA16 cases accounted for 25.96% of HFMD pathogen spectrum in Fujian, with periodic biennial fluctuations characterized by increases in even-numbered years and decreases in odd-numbered years and a post-2023 surged to >50%. CVA16 Cases peaked during spring-summer, with a male-to-female ratio of 1.69:1, predominantly in children aged 1-3 years. Genetically, B1 subgenotype (cluster B1a-c) co-circulated. B1b dominated before 2018, gradually shifting to B1a thereafter, and to B1c (emerging in late 2023) after mid-2023. Conclusion: These findings clarify the long-term distribution and genetic shifts of CVA16 in Fujian, identifying the emerging B1c as a major driver of recent outbreaks and providing a baseline for regional HFMD prevention and vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.